BeyondSpring Inc. (BYSI) Reports Q3 Loss of $0.05 Nov 12, 2025 08:08AM
BeyondSpring Inc. (BYSI) Reports Q2 Loss of $0.10 Aug 13, 2025 06:56PM
BeyondSpring (BYSI) study shows plinabulin response in checkpoint inhibitor failures Jul 7, 2025 07:02AM
BeyondSpring (BYSI) Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel Jun 3, 2025 07:01AM
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.08 May 13, 2025 07:03AM


Jan 28, 2025 07:01AM BeyondSpring (BYSI) Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Nov 11, 2024 08:01AM BeyondSpring (BYSI) Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC
Sep 16, 2024 07:01AM BeyondSpring (BYSI) Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC
Sep 16, 2024 07:00AM BeyondSpring (BYSI) Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel